Literature DB >> 12780671

The effect of ATG on cytokine and cytotoxic T-lymphocyte gene expression in renal allograft recipients during the early post-transplant period.

Tania Simon1, Gerhard Opelz, Rolf Weimer, Manfred Wiesel, Andreas Feustel, Ralf C Ott, Caner Süsal.   

Abstract

BACKGROUND: Despite the long history of ATG use, the exact in vivo mechanism of action remains unclear. In the present study, we analyzed the effect of ATG-induction therapy on expression of 10 immunologically relevant genes in the early post-transplant period.
METHODS: Eight renal allograft recipients received post-transplant prophylactic ATG treatment on 10 consecutive days and an additional three patients received treatment on 5, 6, or 7 consecutive days, respectively. Gene expression was measured at the beginning and the end of therapy and normalized to a control gene using Taqman real-time PCR methodology. Results were compared with those of matched control patients. No patients were diagnosed with rejection.
RESULTS: ATG-treated patients showed decreases in the expression of cytotoxic T cell genes perforin (-56%, p = 0.03) and granzyme B (-45%, p = 0.01) and cytokine gene IFN-gamma (-75%, p = 0.005), and significant increases in the expression of cytokine genes IL-7 (550%, p = 0.04), IL-10 (275%, p = 0.01), IL-15 (417%, p = 0.03), TNF-alpha (615%, p = 0.01), and TGF-beta (235%, p = 0.02). No significant changes were observed in the control group, with the exception of a decrease in IL-10 expression (-42%, p = 0.01). There were no significant changes in IL-12 or Fas-L expression in either group.
CONCLUSION: ATG-induced decreases in the expression of IFN-gamma, perforin, and granzyme B and increases in IL-10 and TGF-beta might be considered beneficial to the recipient, whereas increases in the expression of IL-7, IL-15, and TNF-alpha genes might be involved in immunological processes not effected by ATG that may harm the transplant in the long term.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12780671     DOI: 10.1034/j.1399-0012.2003.00031.x

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  7 in total

1.  The calcineurin inhibitor tacrolimus allows the induction of functional CD4CD25 regulatory T cells by rabbit anti-thymocyte globulins.

Authors:  V D K D Sewgobind; L J W van der Laan; M M L Kho; R Kraaijeveld; S S Korevaar; W Mol; W Weimar; C C Baan
Journal:  Clin Exp Immunol       Date:  2010-05-28       Impact factor: 4.330

2.  Interleukin (IL)-10 induced by CD11b(+) cells and IL-10-activated regulatory T cells play a role in immune modulation of mesenchymal stem cells in rat islet allografts.

Authors:  Yang-Hee Kim; Yu-Mee Wee; Monica-Y Choi; Dong-Gyun Lim; Song-Cheol Kim; Duck-Jong Han
Journal:  Mol Med       Date:  2011-02-25       Impact factor: 6.354

3.  Biomarkers in solid organ transplantation: establishing personalized transplantation medicine.

Authors:  Silke Roedder; Matthew Vitalone; Purvesh Khatri; Minnie M Sarwal
Journal:  Genome Med       Date:  2011-06-08       Impact factor: 11.117

4.  Dissecting the mechanisms involved in anti-human T-lymphocyte immunoglobulin (ATG)-induced tolerance in the setting of allogeneic stem cell transplantation - potential implications for graft versus host disease.

Authors:  Katia Beider; David Naor; Valeria Voevoda; Olga Ostrovsky; Hanna Bitner; Evgenia Rosenberg; Nira Varda-Bloom; Victoria Marcu-Malina; Jonathan Canaani; Ivetta Danilesko; Avichai Shimoni; Arnon Nagler
Journal:  Oncotarget       Date:  2017-10-11

5.  Long-Term Suppression of Circulating Proinflammatory Cytokines in Multiple Sclerosis Patients Following Autologous Haematopoietic Stem Cell Transplantation.

Authors:  Kevin Hendrawan; Melissa L M Khoo; Malini Visweswaran; Jennifer C Massey; Barbara Withers; Ian Sutton; David D F Ma; John J Moore
Journal:  Front Immunol       Date:  2022-01-19       Impact factor: 7.561

6.  Effect of induction therapy on the expression of molecular markers associated with rejection and tolerance.

Authors:  Eva Krepsova; Irena Tycova; Alena Sekerkova; Peter Wohlfahrt; Petra Hruba; Ilja Striz; Birgit Sawitzki; Ondrej Viklicky
Journal:  BMC Nephrol       Date:  2015-08-19       Impact factor: 2.388

7.  Alemtuzumab as Antirejection Therapy: T Cell Repopulation and Cytokine Responsiveness.

Authors:  Anne P Bouvy; Mariska Klepper; Michiel G H Betjes; Willem Weimar; Dennis A Hesselink; Carla C Baan
Journal:  Transplant Direct       Date:  2016-05-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.